Notes Payable and Debt (Details Textual) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended	236 Months Ended	6 Months Ended								6 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Number_Of_Notes	Jun. 30, 2011	Dec. 31, 2011	Jun. 30, 2012	Jun. 30, 2012 RG [Member]	Jun. 30, 2012 ISVP [Member]	Dec. 31, 2011 ISVP [Member]	Dec. 31, 2011 Robert and Thomas Gipson [Member]	Dec. 27, 2011 Robert Gipson [Member]	Dec. 27, 2011 Thomas Gipson [Member]	Jun. 01, 2011 Arthur Koenig [Member]	Dec. 31, 2011 Ingalls Snyder LLC [Member]	Jun. 30, 2012 Molecular Imaging and Other Products [Member]	Jun. 30, 2012 Demand Notes Payable [Member]	Jun. 30, 2011 Demand Notes Payable [Member]	Jun. 30, 2012 Demand Notes Payable [Member]	Jun. 30, 2011 Demand Notes Payable [Member]
Notes Payable and Debt (Textual) [Abstract]
Convertible notes payable	$ 21,827,588		$ 21,827,588		$ 21,827,588	$ 21,827,588				$ 7,172,412					$ 1,000,000
Future payments as a percentage of pre-commercial revenue															2.00%
Notes payables additional compensation as a percentage of future net sales per $1000000 outstanding principle															0.50%
Percentage of shares to be held by purchases considered to determine effective conversion under option 1								19.90%
Percentage of shares to be held by purchases considered to determine effective conversion under option 2								9.99%
Recorded Beneficial Conversion Feature							380,000	1,400,000
Percentage of outstanding common stock									9.99%		50.10%	15.20%	7.00%	9.99%
Demand notes payable value	6,185,000		6,185,000		5,900,000	6,185,000
Interest expenses Related to BCF	0	362,499	0	724,998												105,287	100,078	208,225	186,224
Notes Payable and Debt (Additional Textual) [Abstract]
Unsecured promissory note	1,000,000		1,000,000			1,000,000
Interest expenses	105,716	465,258	209,113	919,009	18,000	14,698,223
Additional Debt					$ 2,525,000
Unsecured convertible promissory notes conversion options			Conversion Policies (i) shares of the Company’s common stock at a conversion price per share of $2.50, (ii) the right to receive future payments related to the Company’s molecular imaging products in amounts equal to 2% of the Company’s pre-commercial revenue related to such products plus 0.5% of future net sales of such products for each $1,000,000 of outstanding principal and interest that a Purchaser elects to convert into future payments, or (iii) a combination of (i) and (ii).
Unsecured convertible promissory notes conversion price per common stock share	$ 2.50		$ 2.50			$ 2.50
Notes Payable, Description			Purchaser is prohibited from effecting a conversion into common stock if at the time of such conversion the common stock issuable to such Purchaser, when taken together with all shares of common stock then held or otherwise beneficially owned by such Purchaser exceeds 19.9%, or 9.99% ISVP, of the total number of issued and outstanding shares of the Company’s common stock immediately prior to such conversion unless and until the Company’s stockholders approve the conversion of all of the shares of common stock issuable there under.
Number of unsecured promissory notes issued			2